Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy

Langenbecks Arch Surg. 2008 May;393(3):423-5. doi: 10.1007/s00423-007-0217-y. Epub 2007 Aug 17.

Abstract

Introduction: Interleukin-6 (IL-6) is a multifunctional cytokine that regulates various aspects of the immune responses, acute phase reactions, and hematopoiesis. In rodent models, IL-6 has been suggested to be one of the essential mediators for optimal acute phase responses to infection and tissue damage. However, in humans, the roles of IL-6 in acute phase responses after surgery remain poorly understood.

Case report: We present the first case report of successful splenectomy and cholecystectomy in a severe autoimmune-associated hemolytic anemia patient during treatment with a humanized anti-IL-6 receptor antibody.

Discussion: This unique case suggests that IL-6 is not an essential cytokine to safely perform surgical intervention and to prevent postoperative complications and that surgical intervention may not be contraindicated but can be selected as a therapeutic modality in patients treated with anti-IL-6 receptor antibody therapy.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adult
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Cholecystectomy*
  • Cholecystitis / surgery
  • Combined Modality Therapy
  • Follow-Up Studies
  • Gallstones / surgery*
  • Humans
  • Male
  • Receptors, Interleukin-6 / antagonists & inhibitors*
  • Splenectomy*
  • Splenomegaly / surgery*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • IL6R protein, human
  • Receptors, Interleukin-6
  • tocilizumab